SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Investing in Ex Ante Regulation: Evidence from Pharmaceutical Patent Examination
16 references·0 citing·46 second hop
Investing in Ex Ante Regulation: Evidence from Pharmaceutical Patent Examination (2020)Investing in Ex Ante Regulation: Evidence…How Do Patents Affect Follow-On Innovation? Evidence from the Human Genome (2019)How Do Patents Affect Follow-…Ex Post Liability for Harm vs. Ex Ante Safety Regulation: Substitutes or Complements? (2018)Ex Post Liability for Harm vs…Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials (2015)Do Firms Underinvest in Long-…Evergreening, patent challenges, and effective market life in pharmaceuticals (2012)Evergreening, patent challeng…Robust Inference With Multiway Clustering (2011)Robust Inference With Multiwa…Examiner Characteristics and Patent Office Outcomes (2011)Examiner Characteristics and …Generic Drug Industry Dynamics (2005)Generic Drug Industry DynamicsMarket Size in Innovation: Theory and Evidence from the Pharmaceutical Industry (2004)Market Size in Innovation: Th…The NBER Patent Citations Data File: Lessons, Insights and Methodological Tools (2001)The NBER Patent Citations Dat…Rational Ignorance at the Patent Office (2001)Rational Ignorance at the Pat…Does Regulation Drive Out Competition in Pharmaceutical Markets? (2000)Does Regulation Drive Out Com…Entry Decisions in the Generic Pharmaceutical Industry (1999)Entry Decisions in the Generi…Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery (1996)Scale, Scope, and Spillovers:…Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act (1992)Brand Loyalty, Entry, and Pri…Liability for Harm versus Regulation of Safety (1984)Liability for Harm versus Reg…Invention, Growth and Welfare. (1970)Invention, Growth and Welfare.The Use of Standards and Prices for Protection of the Environment (1971)Effluent charges and licenses under uncertainty (1976)Monitoring vis-a-vis Investigation in Enforcement of Law (1992)Regulating Service Quality: A Survey (2005)Do data breach disclosure laws reduce identity theft? (2011)Two-Moment Decision Models and Expected Utility Maximization (2016)Another look at the instrumental variable estimation of error-components models (1995)Initial conditions and moment restrictions in dynamic panel data models (1998)Econometric Analysis of Cross Section and Panel Data (2001)Depression Babies: Do Macroeconomic Experiences Affect Risk Taking?* (2011)What Determines Productivity? (2011)Carbon Taxes, Path Dependency, and Directed Technical Change: Evidence from the Auto Industry (2016)Industrial Market Structure and Economic Performance. (1971)Product differentiation advantages of pioneering brands (1980)The economic analysis of advertising (2005)Chapter 28 The Economic Analysis of Advertising (2007)Killer Acquisitions (2020)Can Patents Deter Innovation? The Anticommons in Biomedical Research (1998)Technological Innovation, Resource Allocation, and Growth* (2017)A Toolkit of Policies to Promote Innovation (2019)American Economic Review (2019)What Is a Patent Worth? Evidence from the U.S. Patent “Lottery” (2019)Who Profits from Patents? Rent-Sharing at Innovative Firms* (2019)Federal Courts. Review. Unexplained Dismissal without Prejudice of Intervenor's Counterclaims Seeking Injunctive Relief Is Appealable. Stewart-Warner Corp. v. Westinghouse Elec. Corp. (2d Cir. 1963) (1964)Can Unpredictable New Technology Satisfy Enablement? Enzo Biochem, Inc. v. Calgene, Inc. , 188 F.3d 1362 (Fed. Cir. 1999) (2001)Open Innovation: A New Paradigm for Understanding Industrial Innovation (2006)Innovation and Its Discontents (2011)Resources as dual sources of advantage: Implications for valuing entrepreneurial‐firm patents (2013)Estimating Standard Errors in Finance Panel Data Sets: Comparing Approaches (2006)Bootstrap-Based Improvements for Inference with Clustered Errors (2008)Temperature Shocks and Economic Growth: Evidence from the Last Half Century (2012)Policy Uncertainty and Corporate Investment (2015)Economic Welfare and the Allocation of Resources for Invention (1962)Increasing Returns and Long-Run Growth (1986)Innovation and Learning: The Two Faces of R & D (1989)Measuring Competence? Exploring Firm Effects in Pharmaceutical Research (1994)Entrepreneurship in the large corporation: a longitudinal study of how established firms create breakthrough inventions (2001)Clinical development success rates for investigational drugs (2014)On the Division of Profit in Sequential Innovation (1995)A Reprise of Size and R & D (1996)The benefits and costs of strong patent protection: a contribution to the current debate (1998)On the joint use of liability and safety regulation (2000)Management-Based Regulation: Prescribing Private Management to Achieve Public Goals (2003)Large Risks, Limited Liability, and Dynamic Moral Hazard (2010)The Knowledge Economy (2004)Financial development and innovation: Cross-country evidence (2013)
this work references cited by second hop

References

  • 2011Robust Inference With Multiway Clustering3,241 cited
  • 1996Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery1,389 cited
  • 2001The NBER Patent Citations Data File: Lessons, Insights and Methodological Tools1,085 cited
  • 2004Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry971 cited
  • 1992Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act574 cited
  • 1984Liability for Harm versus Regulation of Safety381 cited
  • 2001Rational Ignorance at the Patent Office376 cited
  • 1970Invention, Growth and Welfare.369 cited
  • 2018Ex Post Liability for Harm vs. Ex Ante Safety Regulation: Substitutes or Complements?347 cited
  • 2019How Do Patents Affect Follow-On Innovation? Evidence from the Human Genome343 cited
  • 2005Generic Drug Industry Dynamics312 cited
  • 2015Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials307 cited
  • 2011Examiner Characteristics and Patent Office Outcomes266 cited
  • 2012Evergreening, patent challenges, and effective market life in pharmaceuticals262 cited
  • 2000Does Regulation Drive Out Competition in Pharmaceutical Markets?

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

237 cited
  • 1999Entry Decisions in the Generic Pharmaceutical Industry228 cited
  • Cited by

    No citing works inside the corpus for this window.